nature portfolio

Corresponding author(s):	Georgia Tsagkogeorga, Hendrik Weisser, Namshik Han
Last updated by author(s):	Jul 4, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics			
For all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a Confirmed			
☐ ☐ The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement		
A stateme	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.			
A description of all covariates tested			
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons			
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)			
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.			
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings			
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
Estimates	of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated		
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
Software an	d code		
Policy information	about <u>availability of computer code</u>		
Data collection	No software used. Data were downloaded from https://maayanlab.cloud/Harmonizome/		
Data analysis	For the machine learning analyses, we developed custom code publicly available at GitHub https://github.com/storm-therapeutics/ML_RNA_methylation. All meta-analyses were performed using the R software environment (v. 4.0.5).		
	custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.		
Data			
,	about <u>availability of data</u>		
- Accession codes	ust include a <u>data availability statement</u> . This statement should provide the following information, where applicable: s, unique identifiers, or web links for publicly available datasets any restrictions on data availability		

- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The Python scripts used for the machine learning analyses are available at GitHub https://github.com/storm-therapeutics/ML_RNA_methylation.

Please select the c	one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.	
∑ Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences	
For a reference copy of	the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf	
Life scier	nces study design	
	sclose on these points even when the disclosure is negative.	
Sample size	No sample size calculation was performed. For the machine learning analyses, we sampled all known RNA methylation genes as our positive class. These were either methyl-writers (known RNA methyltransferases and their partner proteins in protein complexes), or enzymes previously annotated as putative RNA methyltransferases. The remaining genes of the human genome were divided into sets of equal size to the positive samples, and used as negative samples.	
Data exclusions	No data were excluded.	
Replication	To ensure reproducibility, we made our code publicly available at GitHub. We also performed our analyses from a fixed random seed.	
Randomization	Randomization was used in our negative class sampling. We assembled multiple stratified training and test datasets by randomly sampling a number of genes equal to our positive set from the remaining genome, ensuring that all genes of our initial dataset were sampled exactly once.	

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental system	s Methods
n/a Involved in the study	n/a Involved in the study
Antibodies	ChIP-seq
Eukaryotic cell lines	Flow cytometry
Palaeontology and archaeology	MRI-based neuroimaging
Animals and other organisms	·
Human research participants	
Clinical data	
Dual use research of concern	